SHILPAMED · NSE
Shilpa Medicare Limited
₹849.15
-5.72% (-₹51.55)
Prev. close
₹900.7
Volume
15,38,885
Delivery %
46.1%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
none in range
Long-Horizon
1 · 1 bull / 0 neutral / 0 bear
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Shilpa Medicare with a target price of ₹1,160, indicating a 25% potential upside. Growth opportunities are se…” | Anand Rathi AnalysisAnand Rathi | Shilpa Medicare Ltd | PENDING |
Long-Horizon calls · 1yr+ horizon · verdict pending
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Shilpa Medicare; target ₹1,160 in 12 months (~25% upside) driven by expansion of its biologics platform, upco…” | Anand Rathi AnalysisAnand Rathi | Shilpa Medicare | PENDING |
Fundamentals
About Shilpa Medicare Limited
Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers GLP-1; HpAPI; intermediates; peptides; payloads and linkers; biopolymers; microbial and mammalian products; fermentation; small molecules; monoclonal antibodies and recombinant technology; and tablets, capsules, injectables, oral dissolving films, and transdermal patches. Further, it engages in wind power generation activities. The company serves wholesalers, distributors, doctors, pharmacy chain NGOs, hospitals, government institutions, and companies. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Vishnukant Chaturbhuj Bhutada B. Pharm
Headquarters
Raichur
Employees
1,241
Website
vbshilpa.comExchange
View on NSE ↗Key stats
Market cap
₹18,210.62 Cr
P/E ratio (TTM)
65.8
Dividend yield
0.06%
EPS (TTM)
₹14.16
Beta (1Y · daily vs NIFTY 50)
0.81
Beta (5Y · monthly vs NIFTY 50)
0.41
Shares float
9.57 Cr
EPS · quarter ended Jun 2026
₹5.16
Financial Performance
01 · Financials
Net income the series has no figure for is taken from the company's own statements — FY22: profit attributable to owners.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss — as filed
Annual
| Line item | FY22 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹1,159.77 Cr | ₹1,159.77 Cr | ₹1,309.76 Cr | ₹1,548.71 Cr | |
| ₹1,062.63 Cr | ₹1,106.79 Cr | ₹1,155.58 Cr | ₹1,282.68 Cr | |
Profit before share of profit/(loss) of an associates/a joint | ₹97.13 Cr | ₹52.99 Cr | ₹154.18 Cr | ₹266.03 Cr |
Share of profit / (loss) of an associate/joint venture, net of tax | ₹-3.66 Cr | ₹-4.78 Cr | ₹-1.27 Cr | ₹17.12 Cr |
Profit/(loss) before exceptional items and tax | ₹93.47 Cr | ₹48.21 Cr | ₹152.91 Cr | ₹283.15 Cr |
Exceptional Items- (Income) / Expense | ₹8.79 Cr | ₹-6.13 Cr | ₹30.58 Cr | ₹-12.16 Cr |
Profit before tax | ₹102.26 Cr | ₹54.34 Cr | ₹122.33 Cr | ₹295.31 Cr |
| ₹41.68 Cr | ₹22.39 Cr | ₹44.04 Cr | ₹51.99 Cr | |
| ₹59.22 Cr | ₹29.58 Cr | ₹75.99 Cr | ₹247.19 Cr | |
Profit for the year | ₹60.58 Cr | ₹31.96 Cr | ₹78.29 Cr | ₹243.33 Cr |
| ₹-1.36 Cr | ₹-2.37 Cr | ₹-2.30 Cr | ₹3.87 Cr | |
a) Owners of the Company | ₹60.66 Cr | ₹31.87 Cr | ₹78.29 Cr | ₹243.33 Cr |
b) Non Controlling Interest* | ₹-8.02 L | ₹8.09 L | — | — |
a) Owners of the Company | ₹-1.36 Cr | ₹-2.37 Cr | ₹-2.30 Cr | ₹3.87 Cr |
a) Owners of the Company | ₹59.30 Cr | ₹29.50 Cr | ₹75.99 Cr | ₹247.19 Cr |
b) Non Controlling Interest* | ₹-8.02 L | ₹8.09 L | — | — |
Basic (Rs | 7.26 | 3.67 | 4.02 | 12.44 |
Diluted (Rs) | 7.26 | 3.67 | 4.02 | 12.44 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹2,875.50 Cr | ₹2,903.93 Cr | ₹3,093.24 Cr | ₹3,310.68 Cr | ₹3,705.61 Cr | |
| ₹2,875.50 Cr | ₹2,903.93 Cr | ₹3,093.24 Cr | ₹3,310.68 Cr | ₹3,705.61 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹211.61 Cr | ₹109.53 Cr | ₹275.78 Cr | ₹317.38 Cr | ₹437.76 Cr | |
| ₹105.13 Cr | ₹179.92 Cr | ₹136.67 Cr | ₹132.27 Cr | ₹342.18 Cr | |
| ₹-285.50 Cr | ₹-232.61 Cr | ₹-166.58 Cr | ₹-199.13 Cr | ₹-325.92 Cr | |
| ₹25.34 Cr | ₹19.07 Cr | ₹31.76 Cr | ₹28.57 Cr | ₹45.18 Cr | |
Components of Cash and Cash Equivalents | ₹25.34 Cr | — | — | — | — |
Cash in Hand | ₹33.86 L | — | ₹32.62 L | — | — |
Balances with banks - on current accounts | ₹30.04 Cr | — | ₹22.62 Cr | — | — |
Balances with banks - on unpaid dividend accounts | — | — | ₹20.99 L | — | — |
Deposits with original maturity of less than 03 months | ₹3.45 Cr | — | ₹7.28 Cr | — | — |
Fixed deposits having maturity less than 12 months and held as margin money | — | — | ₹1.33 Cr | — | — |
Book overdraft | ₹-8.49 Cr | — | ₹-1.02 L | — | — |
Total Cash and Cash Equivalents | — | — | ₹31.76 Cr | — | — |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Nov 21–Mar 24(11Q) | Apr 24–Jun 24(2Q) | Sep 24 | Dec 24–Sep 25(4Q) | Dec 25–Jun 26(3Q) |
|---|---|---|---|---|---|---|
| Promoter | 53.25% | 50.01% | 44.39% | 44.33% | 44.23% | 40.13% |
| Public | 46.75% | 49.99% | 55.61% | 55.67% | 55.77% | 59.87% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Shilpa Medicare Limited | ₹18,229.20 Cr | ₹931.1 | 65.9 | 7.04 | 9.4% | 0.25 | +19.7% | +160.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Index membership
2 indices
Shilpa Medicare - 16 microcap stocks surge up to 390% in CY26, emerge as multibaggers
The Economic Times · 4 days ago
Shilpa Medicare reports highest ever revenue and EBITDA in Q2 FY27
Shilpa Medicare Limited posted record Q2 FY27 revenue of INR 538 crore, a 35% year‑on‑year rise, and EBITDA of INR 151 crore, up 37% YoY, driven by growth in its API, CDMO, formulation and biologics segments. The half‑year results showed INR 1,007 crore revenue and a 29% EBITDA margin, indicating the company is moving from investment to profit‑generation phases.